Literature DB >> 26268700

BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.

Seo Ki Kim1, Jun Ho Lee2, Jung-Woo Woo1, Inhye Park1, Jun-Ho Choe1, Jung-Han Kim1, Jee Soo Kim1.   

Abstract

BACKGROUND: The necessity of prophylactic central neck dissection is one of debating issues in the treatment of papillary thyroid carcinoma (PTC). In a previous study, the predictive value of BRAF mutation for lymph node metastasis was only significant in 0.5 to 1.0 cm PTC. Thus, we assess the predictive value of BRAF mutation for central lymph node metastasis according to tumor size.
METHODS: Medical records of 3107 patients with PTC who underwent thyroidectomy with central neck dissection were retrospectively reviewed.
RESULTS: BRAF mutation was a predictor for central lymph node metastasis in 2.0 to 4.0 cm PTC (odds ratio [OR] = 3.494; p = .002). Although BRAF mutation was associated with central lymph node metastasis in 0.5 to 1.0 cm PTC in univariate analysis (OR = 1.334; p = .047), this significance was not observed in multivariate analysis (OR = 1.232; p = .163). BRAF mutation was not associated with central lymph node metastasis in other tumor sizes.
CONCLUSION: Prophylactic central neck dissection could be considered in 2.0 to 4.0 cm PTC with positive BRAF mutation.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E1203-E1209, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAF mutation; central lymph node metastasis; central neck dissection; papillary thyroid carcinoma; tumor size

Mesh:

Substances:

Year:  2015        PMID: 26268700     DOI: 10.1002/hed.24192

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Authors:  Carrie C Lubitz; Tiannan Zhan; Viswanath Gunda; Salma Amin; Benjamin J Gigliotti; Abbey L Fingeret; Tammy M Holm; Heather Wachtel; Peter M Sadow; Lori J Wirth; Ryan J Sullivan; David J Panka; Sareh Parangi
Journal:  Thyroid       Date:  2018-02-27       Impact factor: 6.568

2.  Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy.

Authors:  Guoquan Zhu; Yuying Deng; Liqin Pan; Wei Ouyang; Huijuan Feng; Juqing Wu; Pan Chen; Jing Wang; Yanying Chen; Jiaxin Luo
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

3.  Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAFV600E Mutation and Clinicopathological Features.

Authors:  Gui-You Li; Hai-Long Tan; Pei Chen; Hui-Yu Hu; Mian Liu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Deepak Pun; Jin-Dong Li; Zhi-Peng Zhang; Qiong Yang; Peng Huang; Shi Chang
Journal:  Cancer Manag Res       Date:  2020-05-13       Impact factor: 3.989

4.  A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.

Authors:  Hongzhi Ma; Ru Wang; Jugao Fang; Qi Zhong; Xiao Chen; Lizhen Hou; Ling Feng; Xiaohong Chen; Zhigang Huang; Huanhu Zhao
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

5.  BRAF V600E and lymph node metastases in papillary thyroid cancer.

Authors:  Pan Chen; Liqin Pan; Wensi Huang; Huijuan Feng; Wei Ouyang; Juqing Wu; Jing Wang; Yuying Deng; Jiaxin Luo; Yanying Chen
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

6.  Preoperative Prediction of Central Cervical Lymph Node Metastasis in Fine-Needle Aspiration Reporting Suspicious Papillary Thyroid Cancer or Papillary Thyroid Cancer Without Lateral Neck Metastasis.

Authors:  Kai Zhang; Lang Qian; Jieying Chen; Qian Zhu; Cai Chang
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

7.  Clinicopathological Findings Associated With Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study in China.

Authors:  Yimeng Shi; Zheyu Yang; Yu Heng; Huijun Ju; Yu Pan; Yifan Zhang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

8.  The clinical significance of thyroid hormone-responsive in thyroid carcinoma and its potential regulatory pathway.

Authors:  Zhen-Xing Yu; Cheng Xiang; Sheng-Gui Xu; Yang-Ping Zhang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.